title: Probable levetiracetam-related serum alkaline phosphatase elevation.
abstract: BACKGROUND
  Levetiracetam (LEV) is an antiepileptic drug with a favorable tolerability and safety profile with little or no effect on liver function.
  
  
  METHODS
  Here, we reported an epileptic pediatric patient who developed a significant elevation in serum alkaline phosphatase level (ALP) during LEV monotherapy. Moreover, the serum ALP level was surprisingly decreased to normal after LEV discontinuation. The Naranjo Adverse Drug Reaction Probability Scale score was 6, indicating firstly LEV was a probable cause for the increased serum ALP.
  
  
  CONCLUSIONS
  Cautious usage and concerns of the LEV-associated potential ALP elevation should be considered when levetiracetam is prescribed to epilepsy patients, especially pediatric patients.
authors.affiliation: Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022 , Hubei, China.
authors.forename: Nian
authors.initials: N
authors.lastname: Xiong
authors.forename: Lingling
authors.initials: L
authors.lastname: Hou
authors.forename: Na
authors.initials: N
authors.lastname: Lu
authors.forename: Asrah A
authors.initials: AA
authors.lastname: Mohamed
authors.forename: Tao
authors.initials: T
authors.lastname: Wang
authors.forename: Yaling
authors.initials: Y
authors.lastname: Huang
mesh_terms: D000469:Alkaline Phosphatase / Q000097:blood*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood* / Q000209:etiology*; D002648:Child; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D015415:Biomarkers; D000077287:Levetiracetam; D000469:Alkaline Phosphatase; D010889:Piracetam